Dr. Reddy's Q4 Results Preview: Biosimilars To Drive Revenue Growth
Dr. Reddy's Laboratories Ltd. is set to report its fourth-quarter earnings on May 9. The pharma major is expected to see net profit and revenue growth during the January-March period.
Revenue is estimated to rise 15% year-on-year to Rs 8,359.7 crore, according to consensus of analysts tracked by Bloomberg. While net profit is estimated to grow 11.37% to Rs 1,459 crore.
Ebitda is expected to jump 23.8% to Rs 2,268.6 crore, while margin is anticipated at 27.10%.
The company's revenue growth is primarily expected to be driven by the biosimilar pipeline and key launches in the Indian market. The domestic formulations business is also forecasted to be a significant contributor, with a projected 21% YoY growth, fueled by the integration of the Sanofi portfolio.
Dr. Reddy's Laboratories Q4 FY25 Preview (Consolidated YoY)
Revenue may rise 15.5% at Rs 8,359.7 crore.
Ebitda may rise 23.8% at Rs 2,268.6 crore.
Ebitda margin expected at 27.10%.
Net profit may rise 11.37% at Rs 1,459 crore.
While US sales are expected to grow, HDFC Securities predicts a more modest 3% YoY increase, driven by generic Revlimid sales, which will be partially offset by price and market share erosion in the base business, due to increased competition. The brokerage also noted a 4% quarter-on-quarter growth in the US business due to generic Revlimid sales.
Nuvama highlighted the vaccines business as a key driver of growth in India, and also sees potential benefits from New Respiratory Therapy products in the EU.
Both brokerages expect gross and Ebitda margins to remain steady.
What To Watch Out For
Investors will be keenly watching for updates on potential US launches over the next 12-18 months, as well as the performance of licenses and partnerships formed in recent years. These factors will be crucial in determining the company's growth trajectory in the near future.
Brokerage Views
US business to see 4% QoQ growth due to gRevlimid sales.
Growth will be partly offset by price and market share erosion in the base business, due to incremental competition in key products.
India to see 15% YoY growth on incremental sales from acquired vaccine business from Sanofi.
NRT business has been factored in.
Gross margin and Ebitda margin are expected to remain steady.
Vaccines business a key driver of growth in India.
Sees potential benefits from New Respiratory Therapy products in the EU.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
